Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65212, USA.
Am J Physiol Cell Physiol. 2011 Nov;301(5):C1161-74. doi: 10.1152/ajpcell.00486.2010. Epub 2011 Aug 10.
Using a combination of wild-type (WT) and caveolin-2 (Cav-2) knockout along with retroviral reexpression approaches, we provide the evidence for the negative role of Cav-2 in regulating anti-proliferative function and signaling of transforming growth factor β (TGF-β) in endothelial cells (ECs). Although, TGF-β had a modest inhibitory effect on WT ECs, it profoundly inhibited proliferation of Cav-2 knockout ECs. To confirm the specificity of the observed difference in response to TGF-β, we have stably reexpressed Cav-2 in Cav-2 knockout ECs using a retroviral approach. Similar to WT ECs, the anti-proliferative effect of TGF-β was dramatically reduced in the Cav-2 reexpressing ECs. The reduced anti-proliferative effect of TGF-β in Cav-2-positive cells was evidenced by three independent proliferation assays: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), cell count, and bromodeoxyuridine incorporation and correlated with a loss of TGF-β-mediated upregulation of cell cycle inhibitor p27 and subsequent reduction of the levels of hyperphosphorylated (inactive) form of the retinoblastoma protein in Cav-2 reexpressing ECs. Mechanistically, Cav-2 inhibits anti-proliferative action of TGF-β by suppressing Alk5-Smad2/3 pathway manifested by reduced magnitude and length of TGF-β-induced Smad2/3 phosphorylation as well as activation of activin receptor-like kinase-5 (Alk5)-Smad2/3 target genes plasminogen activator inhibitor-1 and collagen type I in Cav-2-positive ECs. Expression of Cav-2 does not appear to significantly change targeting of TGF-β receptors I and Smad2/3 to caveolar and lipid raft microdomains as determined by sucrose fractionation gradient. Overall, the negative regulation of TGF-β signaling and function by Cav-2 is independent of Cav-1 expression levels and is not because of changing targeting of Cav-1 protein to plasma membrane lipid raft/caveolar domains.
利用野生型 (WT) 和 Cav-2 (Cav-2) 敲除的组合以及逆转录病毒再表达方法,我们提供了证据表明 Cav-2 在调节转化生长因子β (TGF-β) 在血管内皮细胞 (ECs) 中的抗增殖功能和信号转导中起负作用。尽管 TGF-β 对 WT ECs 有适度的抑制作用,但它却显著抑制了 Cav-2 敲除 ECs 的增殖。为了确认对 TGF-β 反应的观察到的差异的特异性,我们使用逆转录病毒方法在 Cav-2 敲除 ECs 中稳定地再表达 Cav-2。与 WT ECs 相似,TGF-β 的抗增殖作用在 Cav-2 再表达 ECs 中显著降低。在 Cav-2 阳性细胞中,TGF-β 的抗增殖作用降低的证据来自三种独立的增殖测定:3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐 (MTT)、细胞计数和溴脱氧尿苷掺入,并与 TGF-β 介导的细胞周期抑制剂 p27 上调的丧失以及随后在 Cav-2 再表达 ECs 中视网膜母细胞瘤蛋白的高磷酸化(失活)形式的水平降低相关。从机制上讲,Cav-2 通过抑制 Alk5-Smad2/3 途径来抑制 TGF-β 的抗增殖作用,表现在 TGF-β 诱导的 Smad2/3 磷酸化的幅度和长度降低,以及激活激活素受体样激酶-5 (Alk5)-Smad2/3 靶基因纤溶酶原激活物抑制剂-1 和胶原类型 I 在 Cav-2 阳性 ECs 中。通过蔗糖分级梯度确定,Cav-2 的表达似乎不会显著改变 TGF-β 受体 I 和 Smad2/3 向质膜脂筏/小窝微域的靶向,而 Smad2/3 的靶向。总体而言,Cav-2 对 TGF-β 信号转导和功能的负调节独立于 Cav-1 表达水平,并且不是因为改变 Cav-1 蛋白向质膜脂筏/小窝域的靶向。